Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Efficacy and Safety of FOLFOX-4 Plus Cetuximab Versus UFOX Plus Cetuximab.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Signed written informed consent~* Inpatient or outpatient ≥ 18 years of age~* Diagnosis of histologically confirmed adenocarcinoma of the colon or rectum~* First occurrence of metastatic disease (not curatively resectable)~* Presence of at least one lesion measurable uni dimensionally by computerised tomography (CT) scan or magnetic resonance imaging (MRI). (Target lesion(s) must not lie within an irradiated area)~* Life expectancy of ≥ 3 months~* Karnofsky performance status of ≥ 60, at study entry~* White blood cell count (WBC) ≥ 3 x 10\^9/L, with neutrophils ≥ 1.5 x 10\^9/L, platelets ≥ 100 x 10\^9/L, and hemoglobin ≥ 9 g/dL~* Aspartate transaminase and alanine transaminase ≤ 2.5 x Upper Limit of Normal (ULN) (≤ 5 x ULN if liver metastasis are present)~* Normal serum creatinine (in case of elevated creatinine, labelled ethylenediaminetetraacetic acid clearance ≥ 65 mL/min is acceptable)~* Effective contraception for both male and female subjects if the risk of conception exists~* Tumor biopsy or archived sample available~Exclusion criteria:~* Brain metastasis and/or leptomeningeal disease (known or suspected)~* Previous chemotherapy for colorectal cancer except adjuvant treatment with progression of disease documented \> 6 months after end of adjuvant treatment.~* Previous oxaliplatin-based chemotherapy~* Surgery (excluding diagnostic biopsy) or irradiation within 4 weeks prior to randomization~* Concurrent or previous chronic systemic immune therapy, targeted therapy, anti-vascular epithelial growth factor (VEGF) therapy, epidermal growth factor receptor (EGFR) pathway targeting therapy not indicated in the study protocol~* Concurrent hormonal therapy not indicated in the study protocol except for physiologic replacement or contraception~* Clinically relevant coronary artery disease, history of myocardial infarction in the last 12 months, or high risk of uncontrolled arrhythmia~* Peripheral neuropathy \>grade 1~* Known hypersensitivity reaction to any of the components of the treatment.~* Any concurrent malignancy other than basal cell cancer of the skin, or pre-invasive cancer of the cervix. (Subjects with a previous malignancy but without evidence of disease for ≥ 5 years will be allowed to enter the study)~* Pregnancy (absence to be confirmed by ß-human chorionic gonadotrophin test) or lactation period~* Known drug abuse/alcohol abuse~* Legal incapacity or limited legal capacity~* Medical or psychological condition which in the opinion of the investigator would not permit the subject to complete the study or sign meaningful informed consent~* Participation in another clinical study within the 30 days before randomization~* Significant disease which, in the investigator's opinion, would exclude the subject from the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): UFOX + Cetuximab
- 2 (Type: ACTIVE_COMPARATOR): FOLFOX4 + Cetuximab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete